Search results for "L. Bueno. Mechanisms involved in bacterial pathogen-induced intestinal mucosal barrier disruption: Therapeutic interest of mecha"
We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Denmark. The product is commercialized under the brand UrinCUR / Utipro plus and it is already present in Sweden, Norway and Finland, distributed as well by our partner RFSU.
Following the publication of the experimental study by Fraile B et al.
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys
XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants.
UTIPRO® PLUS AF
Utipro® Plus AF is intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections.
Health Aff (Millwood) 2018 Apr;37(4):662-669. doi: 10.1377/hlthaff.2017.1153. Epub 2018 Mar 21.
Abstract
In order to further disseminate its proprietary barrier technology, on which the new concept “mucoprotection” is based, and as part of its continuous investment in its products´ reputation, Noventure has just participated in this year´s ESPGHAN Congress, held in Prague.
Noventure is proud to announce the launch of XILAPLUS® in France by its long-term partner company Therabel, under the brand name Diastil Diarrhée.
Urologia Internationalis. Published on line: April 8, 2016
Objective:
To assess the efficacy and safety of a new medical device (MD; a capsule whose main component is a cross-linked protein) in the prevention of uncomplicated cystitis recurrences.
Allergy, Asthma & Clinical Immunology2018
Abstract:
Background
To assess the effects of Rhinosectan® spray, a medical device containing xyloglucan, on nasal ciliary function (in MucilAir™Nasal cells).
Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland, and Norway. Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different etiologies in adults and children.